Strategic Analysis of the Top Companies Investments in Liraglutide Market

1. Global Liraglutide Market 2018 By Manufacturers, Regions, Type And Application, Forecast To 2023 Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition. This report focuses on the Liraglutide in global market, especially in North America, Europe and Asia- Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The total amount of Patents about Liraglutide are 1871, among those Patents, 44%is about application, 26%is about Combination therapy, and 12%is about Preparation method. In these patents, accounting for Europe is the largest, followed by North America, and finally Asia. Get PDF Sample with Technological trends at : https://www.futuregenicreports.com/Request- Sample/102641 The application of Liraglutide Liraglutide for the treatment of type 2 diabetes mellitus Liraglutide 1.2 mg daily in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended as an option for the treatment of people with type 2 diabetes, only if used as described for exenatide in 'Type 2 diabetes: the management of type 2 diabetes' Liraglutide 1.2 mg daily in dual therapy regimens (in combination with metformin or a sulphonylurea) is recommended as an option for the treatment of people with type 2 diabetes, only if the person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and the person is intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated. Obtain Report Details with technological advancement at : https://www.futuregenicreports.com/Reports/Liraglutide-Market

2. Liraglutide 1.8 mg daily is not recommended for the treatment of people with type 2 diabetes. The Committee concluded that the evidence provided was not robust enough to allow it to recommend liraglutide as a cost-effective alternative to either thiazolidinediones or DPP-4 inhibitors as a triple therapy regimen, however it believes liraglutide is a cost-effective treatment option relative to exenatide. Taking into account the lack of clinical trial evidence showing a significant benefit from increasing the liraglutide dose from 1.2 mg to 1.8 mg, the widely varying ICERs and the uncertainty in the economic analysis, the Committee was unable to recommend liraglutide 1.8 mg for the treatment of type 2 diabetes. The Committee concluded that people with type 2 diabetes currently receiving liraglutide who do not meet the criteria specified in section 1.1 or 1.3, or who are receiving liraglutide 1.8 mg, should have the option to continue their current treatment until they and their clinicians consider it appropriate to stop. The worldwide market for Liraglutide is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. Market Segment by Manufacturers, this report covers HEC Pharm Bachem Bharat Pharmaceuticals Kingpep Biotechnology Shenzhen JYMed Technology Wuxi Asiapeptide AmbioPharm Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Market Segment by Type, covers Pills Liquid Market Segment by Applications, can be divided into

3. Hospital Drug Store About Us: Future Generic Reports is a market research and consulting organization, offering premium collection of market research reports, custom research and consulting services to corporations, no-profit organizations and government institutions across the globe. The wide range of information is presented by a team of well-trained researchers of specific sectors through exhaustive research. We deliver premier market research services that cover all industry verticals, including chemicals and material, automotive, healthcare, electronics & semiconductor, food and beverage, pharmaceuticals and technology and media. We believe in building an eternal bond with our clients through offering them inclusive research study meeting their specific requirements. Our services are tailored specifically to our clients by proposing them the potential outcome, based on our in-depth analysis and insights for exploring the growth strategies through providing the best possible decision for quality production. Contact Us: Future Genic Reports 244, Madison Avenue New York City, NY - 10016 United States Toll Free +1- 844-445-2861 Email: sales@futuregenicreports.com